Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health. We do this by discovering, developing, manufacturing and marketing products that combat major threats to the health of people worldwide. Our specialty is fighting infectious diseases—a growing healthcare challenge.
Innovation is the drive force behind our strong research & development (R&D) pipeline, with promising products in pre-clinical and clinical development. Crucell product candidates include flu-mAb, and antibody product effective against a broad range of influenza virus strains, tuberculosis and malaria vaccines, as well as a rabies monoclonal antibody combination-all produced on our unique PER.C6® human-cell technology.
Currently we are combating twelve major infectious diseases with our range of marketed vaccines in the paediatric, travel & endemic and respiratory fields.
The combination of our innovative technologies and creative minds drives Crucell’s success, which we measure in human and business terms.
Johnson & Johnson completed the tender offer for Crucell N.V. (Crucell) on 22nd February 2011 and declared the offer unconditional. As a result, Crucell will now operate as the center for vaccines within the Johnson & Johnson pharmaceuticals group.
Headquartered in Leiden, the Netherlands, Crucell currently employs 1400 people and has offices in China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, the UK the USA and Vietnam.